PapersFlow Research Brief
Dialysis and Renal Disease Management
Research Guide
What is Dialysis and Renal Disease Management?
Dialysis and Renal Disease Management encompasses clinical strategies for evaluating, classifying, and treating chronic kidney disease (CKD) through estimated glomerular filtration rate (eGFR) calculations, guideline-based care, and dialysis therapies to slow progression and manage complications in patients with impaired kidney function.
The field includes over 101,139 published works on methods to estimate glomerular filtration rate from serum creatinine for accurate CKD staging. Levey et al. (2009) introduced a new equation in 'A New Equation to Estimate Glomerular Filtration Rate' that improved precision over prior methods in patients with CKD. Go et al. (2004) demonstrated in 'Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization' a graded association between reduced eGFR and increased risks of death, cardiovascular events, and hospitalization.
Research Sub-Topics
Glomerular Filtration Rate Estimation
This sub-topic develops and validates equations like CKD-EPI and MDRD for estimating GFR from serum creatinine and demographic factors. Researchers compare accuracy across populations and refine models for diverse ethnic groups.
Chronic Kidney Disease Classification
This sub-topic examines K/DOQI and KDIGO guidelines for stratifying CKD stages based on GFR and albuminuria. Researchers study prognostic implications and updates to classification systems for better risk assessment.
Dialysis Adequacy Assessment
This sub-topic evaluates metrics like Kt/V and urea reduction ratio to measure hemodialysis and peritoneal dialysis efficiency. Researchers investigate personalized dosing and outcomes related to dialysis dose optimization.
Renin-Angiotensin System Inhibitors in CKD
This sub-topic analyzes the benefits and risks of ACE inhibitors and ARBs in advanced kidney disease, focusing on hyperkalemia and progression. Researchers conduct trials on continuation versus discontinuation strategies.
Epidemiology of Chronic Kidney Disease
This sub-topic tracks global burden, risk factors, and disparities in CKD incidence and prevalence using GBD studies. Researchers model trends and project future healthcare needs based on demographic shifts.
Why It Matters
Dialysis and renal disease management directly impacts patient outcomes by enabling early CKD detection and intervention to prevent end-stage kidney disease. Levey et al. (2009) showed in 'A New Equation to Estimate Glomerular Filtration Rate' that their equation provides accurate eGFR estimates, facilitating better staging and treatment in over 101,139 studies. Go et al. (2004) found in 'Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization' that reduced eGFR independently raises death risk in community populations, guiding therapies like those in Stevens et al. (2024) 'KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'. Recent FDA breakthrough designations for Nephrodite's Holly implantable dialysis system target end-stage kidney disease affecting over 850,000 U.S. patients with annual costs exceeding $50 billion.
Reading Guide
Where to Start
'K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification' by Levey et al. (2002) first, as it provides foundational CKD staging and public health context essential for understanding subsequent eGFR and management papers.
Key Papers Explained
Levey et al. (1999) 'A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation' introduced the MDRD equation; Levey et al. (2006) 'Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate' standardized it for labs; Levey et al. (2009) 'A New Equation to Estimate Glomerular Filtration Rate' refined accuracy further. Go et al. (2004) 'Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization' links these estimates to outcomes, while Stevens et al. (2024) 'KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease' updates guidelines building on them.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Preprints cover 'KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)' with management figures for dialysis types; 'Contemporary management of advanced chronic kidney ...' discusses SGLT2 inhibitors and GLP-1 agonists; FDA news highlights Nephrodite's Holly implantable dialysis system.
Papers at a Glance
In the News
Q&A: Implantable dialysis device receives FDA ...
In December, the FDA granted breakthrough status for an implantable kidney replacement system for patients with end-stage kidney disease, according to a company press release.
Nephrodite Earns FDA's First Breakthrough Device ...
The designation recognizes Holly as a novel, transformative therapy addressing end-stage kidney disease (ESKD) which affects more than 850,000 people in the U.S., costing more than $50 billion annu...
Continuous dialysis implant wins FDA Breakthrough ...
The company is also seeking investors through a Series A priced equity funding round after previously raising an amount that Shah described as in “the low seven figures.”
US FDA grants breakthrough designation for implantable ...
Holly implantable dialysis device **Nephrodite has announced that the US Food and Drug Administration (FDA) has granted breakthrough device designation to the company’s Holly implantable, continuo...
FDA grants Breakthrough Device status to Nephrodite's ...
* Nephrodite Inc.'s Holly system is recognized as a transformative therapy for end-stage kidney disease, receiving FDA Breakthrough Device Designation.
Code & Tools
This project aims to provide a no-code deployment system for private medical large language models, focusing on knowledge enhancement and clinical ...
`kfre`is a Python library designed to estimate the risk of chronic kidney disease (CKD) progression over two distinct timelines: 2 years and 5 year...
## Clinical Coding of Patients with Kidney Disease The*epocakir*package makes clinical coding of patients with kidney disease using clinical prac...
The goal of this package is to establish well tested, comprehensive functions for the detection of Acute Kidney Injury (AKI) in time series data, a...
Kidney disease is a chronic (long-lasting) health condition that affects how well your kidneys filter waste and excess fluids from your blood.
Recent Preprints
KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)
S95 Appendix Figure 1. Management of anemia in chronic kidney disease G5 receiving hemodialysis S96 Appendix Figure 2. Management of anemia in chronic kidney disease not receiving dialysis S97 Appe...
Contemporary management of advanced chronic kidney ...
The management of CKD has evolved dramatically, shifting from a singular focus on RAS inhibition to a broader, mechanism-based therapeutic framework. Robust evidence now supports the use of SGLT2 i...
Management of blood pressure in adults, children and young people on dialysis: UK kidney association clinical practice guideline
People with end stage kidney disease receiving dialysis have a very risk of cardiovascular disease and mortality. Hypertension is a modifiable risk factor for cardiovascular disease and mortality, ...
Caring for Patients With Advanced Chronic Kidney Disease: Dietary Options and Conservative Care Instead of Maintenance Dialysis
gradual, individualized dialysis transition. Patient empowerment is vital, including CKD education and involvement in decision making. These ideas may help patients, their families, and clinical te...
Kidney diseases - Latest research and news
* ### Impact of citrate dialysate on middle molecular weight uremic toxin adsorption and removal in high-flux and MCO dialysis membranes * Miquel Gomez * Diana Rodriguez-Espinosa * Francisco Madu...
Latest Developments
Recent developments in dialysis and renal disease management as of February 2026 include the approval of several new medications in 2025 targeting specific causes of kidney damage, such as Ozempic (semaglutide) for protecting kidneys in adults with type 2 diabetes and chronic kidney disease (kidney.org, healthtree.org). Additionally, clinical trials are exploring innovative treatments like vonsetamig for decreasing anti-HLA antibodies to facilitate kidney transplants (UCSF, ucla.clinicaltrials.researcherprofiles.org). Advances also include research on artificial kidneys, with efforts aiming for clinical availability by 2030 (The Kidney Project). Furthermore, new drugs such as SGLT2 inhibitors and GLP1 agonists are recognized for managing CKD in 2026 (healthtree.org).
Sources
Frequently Asked Questions
What is the most accurate equation for estimating GFR from serum creatinine?
Levey et al. (2009) developed 'A New Equation to Estimate Glomerular Filtration Rate' using data from the National Institute of Diabetes and Digestive and Kidney Diseases, outperforming measured creatinine clearance. The equation from Levey et al. (1999) in 'A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation' from the MDRD Study provided superior accuracy in CKD patients. Levey et al. (2006) refined it in 'Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate' for GFR under 90 mL/min per 1.73 m².
How does CKD classification affect management?
Levey et al. (2002) established in 'K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification' a system based on GFR stages to identify rising kidney failure incidence and high costs in the U.S. This framework supports risk stratification for earlier interventions. Stevens et al. (2024) updated it in 'KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease' for global application.
What risks are associated with reduced GFR?
Go et al. (2004) reported in 'Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization' an independent graded link between lower eGFR and higher death, cardiovascular events, and hospitalization risks in large populations. These findings emphasize CKD's public health role beyond end-stage disease.
Should ACE inhibitors be continued in advanced CKD?
Ahmed et al. (2016) examined in 'Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?' the balance of cardiovascular benefits against GFR loss risks in CKD with high CVD prevalence. Prior research focused on blood pressure and proteinuria reduction.
What are recent developments in dialysis management?
The FDA granted breakthrough device designation to Nephrodite's Holly implantable continuous dialysis system for end-stage kidney disease patients. Preprints like 'KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)' provide figures for anemia management in hemodialysis, peritoneal dialysis, and non-dialysis CKD.
Open Research Questions
- ? How can eGFR equations be optimized for diverse populations beyond U.S. and Japanese cohorts, as implied by Matsuo et al. (2009)?
- ? What are the long-term effects of continuing ACEI/ARB in advanced CKD on cardiovascular outcomes versus GFR decline, per Ahmed et al. (2016)?
- ? How do emerging therapies like SGLT2 inhibitors integrate with dialysis in end-stage disease?
- ? What factors drive the global CKD burden trends identified by Bikbov et al. (2020)?
- ? Can conservative care with low-protein diets replace dialysis in select advanced CKD patients?
Recent Trends
FDA granted breakthrough designations in December 2025 to Nephrodite's Holly implantable dialysis system for end-stage kidney disease impacting over 850,000 U.S. patients at $50 billion annual cost.
Preprints from late 2025 include 'KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)' with anemia protocols for hemodialysis and peritoneal dialysis, plus 'Management of blood pressure in adults, children and young people on dialysis' noting 90% hypertension prevalence.
Gomez et al. studied citrate dialysate effects on uremic toxin removal in high-flux membranes.
2025Research Dialysis and Renal Disease Management with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Dialysis and Renal Disease Management with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.